Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : ADOT - BIOMODA: Profitable Technology with Purpose -- Ignore unavailable to you. Want to Upgrade?

To: dexx who wrote (1575)	9/9/1998 1:00:00 PM
From: DARPA	Respond to of 4650

Thanks Dexx. I agree. Biomoda does have great talent. And I am excited about the potential of their technology, not just because of the investment potential, but also because the ability to cure cancer through ingestion of radioactive porphyrin is a very humanitarian discovery in an of itself. I have read LungCheck's site and have studied Biomoda's site as well. This is promising. But, as per July's Executive Summary, Biomoda's products are in development stage and it may be a while before definitive revenues show up. Am I happy about ADOT's 22% ownership (with option for 27%)?> - you bet. But, the company will "realistically require investment of $9-$10 million from early investor/partners through the year 2000. Additional funding may be required in years 2001-2003 to finalize product development and improve the success of the products in the marketplace. The Company intends to be listed on a major U.S. stock exchange within 5-6 years. So you see, there is considerable work in front of us before $$$ start to come in. Lots can happen. Not the least of which ADOT's % ownership could become diluted in the process (if anyone has experience or can comment on potential dilution of ADOT's 22/27% ownership of Biomoda, it would be appreciated.) In addition to share dilution, lots of other technologies are also being developed (for example, see the Gamma Knife - very cool cancer treatment in early stage of adoption). For immediate revenue, we need to rely on ADOT's sales. To that extent, I want to know who the two customers are and if it can be found out without jeopardizing sales, the other "7 qualified leads". To me, this part of the release sniffs of hype. Not impressed with or interested in having that in press release content, although I was happy to hear the news. Signed contracts are golden. Keep pressing the qualified leads, but keep that out of the press releases. IMHO. PS, I've been here since the first post. And will stay.